ImmuneOncia Therapeutics, Inc. (KOSDAQ:424870)
South Korea flag South Korea · Delayed Price · Currency is KRW
3,440.00
+45.00 (1.33%)
At close: Aug 11, 2026

ImmuneOncia Therapeutics Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-28,544-27,363-5,6878,864-3,492-60,490
Depreciation & Amortization
890.41890.411,0511,0311,0811,026
Loss (Gain) From Sale of Assets
---0.771.383.18
Stock-Based Compensation
409.46409.46981.91,3113,9911,948
Other Operating Activities
-550.8-269.92-5,982-19,648-10,76748,945
Change in Accounts Receivable
421.83421.83-410.83622.65-710.85-
Change in Unearned Revenue
-----4,9526,884
Change in Other Net Operating Assets
1,0753,136-4,623-518.09-452.73-292.68
Operating Cash Flow
-26,298-22,775-14,670-8,337-15,301-1,976
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-348.16-329.97-86.87-428.43-36.21-101.34
Sale (Purchase) of Intangibles
-154.86-137.74-52.09--52.4-4.85
Investment in Securities
-3,028-12,1001,900-5,0006,0002,708
Other Investing Activities
-571.74-545.95-32.696.71-8.47-840
Investing Cash Flow
-4,102-13,1141,728-5,3325,9031,762

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Repaid
--51.87-48.87-103.65-232.1-210.93
Net Debt Issued (Repaid)
-52.17-51.87-48.87-103.65-232.1-210.93
Issuance of Common Stock
36,32736,0212598,000-6,000
Other Financing Activities
-90.7-69.1-3.18-0--
Financing Cash Flow
36,18435,900206.967,896-232.124,289

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
0.17-4.09-40.44218.5
Miscellaneous Cash Flow Adjustments
-0-0--0--
Net Cash Flow
5,78411.34-12,731-5,773-9,59024,293

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-26,647-23,105-14,757-8,766-15,337-2,078
Free Cash Flow Growth
------
Free Cash Flow Margin
-44825.92%-20776.54%-2254.59%-7968.93%-198.32%-5779.96%
Free Cash Flow Per Share
-365.28-329.02-262.08-167.13-294.29-44.72
Levered Free Cash Flow
--13,443-10,722-4,331-11,1882,384
Unlevered Free Cash Flow
--13,440-10,718-4,329-11,1882,384

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
5.125.126.93---
Cash Income Tax Paid
365.61355.61-11.0450.1815.815.98
Change in Working Capital
1,4973,558-5,034104.56-6,1166,591